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REVIEW
Abstract: Pharmacological treatment of cerebrovascular disorders was introduced at the
beginning of the 20th Century. Since then, a multitude of studies have focused on the
development of a consensus for a well defined taxonomy of these disorders and on the
identification of specific patterns of cognitive deficits associated with them, but with no clear
consensus. Nevertheless, citicoline has proved to be a valid treatment in patients with a
cerebrovascular pathogenesis for memory disorders. A metanalysis performed on the entire
database available from the clinical studies performed with this compound confirms the
experimental evidence from the animal studies which have repeatedly described the multiple
biological actions of citicoline in restoring both the cell lipid structures and some
neurotransmitter functions.
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Introduction
Citicoline is the name for cytidine 5′-diphosphocholine (CDP-choline) when this is
used as an exogenous sodium salt. In fact, CDP-choline is an endogenous nucleotide
naturally found in the body where it is an essential intermediate in the synthesis of
the major phospholipid of the cell membranes, phosphatidylcholine (PtdCho). This
type of synthesis is called the Kennedy pathway (Fernandez-Murray and McMaster
2005).
As a drug, citicoline has been proposed for use in traumatic brain injures, stroke,
vascular dementia, Parkinson’s disease, and brain aging (Blount et al 2002) where it
has the function of stabilizer of cell membranes and reduces the presence of free
radicals (Zweifler 2002). In particular, there is some evidence of a stimulating role
of citicoline for the release of dopamine neurotransmitters in the brain (Fonlupt et al
1985).
Citicoline, by activating the central cholinergic system, also increases plasma
adrenocorticotropic hormone (ACTH) levels and potentiates serum thyrotrophin
(TSH) levels. The stimulation of central nicotinic and muscarinic receptors also
increases growth hormone (GH) and luteinizing hormone (LH) serum levels (Cavun
and Savci 2004). This activity on the cholinergic system is of high therapeutic
usefulness in those clinical conditions where alterations of acetylcholine metabolism
are considered one of the primary causes of disease (Shen 2004), eg, Alzheimers
Disease (AD).
The biological activity attributed to citicoline has suggested a possible role of
citicoline on improving memory (McDaniel 2003). Some clinical studies have given
evidence to this hypothesis (Agnoli et al 1989; Spiers et al 1996) and there is a
proposal for studying citicoline in mild cognitive impairment (MCI) with the aim of
confirming both its efficacy in these patients and a possible role as a retardant agent
for the cognitive deterioration of the eventual subsequent dementia (Abad-Santos
2002).
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More than 11 000 people, including patients and volunteers
have been studied for evaluating citicoline therapeutic
effects. 1372 of these patients were included in studies
concerning citicoline efficacy in acute ischemic stroke and
pooled together in a meta-analysis of these studies (Davalos
et al 2002). This analysis showed that citicoline increases
the probability of a complete recovery after three months
from moderate to severe stroke when it is administered
within 24 hours from the event, although the odds ratio of
improving with citicoline is only 1.33. Citicoline’s
therapeutic action has been attributed to its restoring activity
of the PtdCho levels which decrease after a stroke (Rao et
al 2006).
In stroke patients there seems to be a particular problem
in efficiently delivering citicoline at high enough blood
levels required to be effective, and to avoid those differences
in results evidenced between studies done by intravenous
(IV) administration of the drug and oral administration, a
more effective preparation for the oral administration is
suggested (Rao and Hatcher 2005).
Vascular dementia
The clinical picture of cognitive and behavioural disorders
associated with chronic cerebrovascular disorders (CVD)
is much less clear-cut and defined than the picture associated
with Alzheimer’s dementia. The definition itself of vascular
dementia (VD) has been under discussion for a long time
and the heterogeneity of the conditions of patients included
in this group is probably higher than the similarities between
patients (Wallin et al 2003).
Correlative studies
When attempts are made to identify relevant relationships
between neuroimaging and cognitive patterns, most of the
studies have not been able to point out consistent and reliable
concordance between these two domains (Paul et al 2003;
Sweet et al 2003; Gunstad et al 2004) primarily because of
the low power of these studies due to the small number of
cases (Cohen et al 2003).
There is evidence of different patterns of cognitive
deficits in patients with chronic cerebrovascular disorders
when it has been possible to differentiate between those
with prevalent signs of altered hippocampal volume from
those with diffuse alterations in the grey and white matter
(Mungas et al 2005). Memory deficits are more relevant in
the former group and executive function impairment in the
latter group. These findings do not overlap with those that
emerge when subcortical dementia is studied as an
independent clinical entity characterized by defined
quantities of leuakariosis. These neuroimaging findings are
commonly associated with deficits in executive function,
while memory disorders are considered to be a direct
function of cortical impairment (Price et al 2005). In some
instances, this apparent contrast among study results was
explained by the different origin of the patients included;
eg, when patients from stroke clinics are compared with
patients from memory clinics, the specificity of relationship
between neuroimaging and functional data is much weaker
in the latter group (Rockwood et al 2006). A proposal has
been presented that considers subcortical dementia as a
specific form of vascular dementia related to a
predominantly small vessel pathogenesis. Mixed
dementia is then considered as a nonspecific form of
vascular dementia and related to prevalent large infarcts
pathogenesis associated with cortical primary atrophy
(Jellinger 2004). This model points out the need of
considering possible different pathogeneses for different
forms of vascular encephalopathy, but does not yet help
in identifying specific cognitive patterns of decline
associated with them. These issues have largely
confounded the studies of citicoline.
Population studies
In studies aimed to identify the relationship between
presence of cerebrovascular disorders and prevalence of
cognitive disorders in the general population, signs of
vascular pathogenesis such as arterial stiffness or generalized
atherosclerosis are consistently related to cognitive
deterioration which ranges from mild severity to dementia
(Hanon et al 2005; Vinkers et al 2005).
Specificity of cognitive deficits
The most common way of defining the specificity of
cognitive deficits in vascular dementia is based on
comparison with AD patients. Cognitive deficits in these
two forms of dementia are consistently found to be more
severe in AD patients, while the specificity of deficits in
vascular dementia is less clear and more difficult to be
replicated in diverse studies. Executive function deficits
seem to be more prevalent in vascular dementia, while
memory deficits are more typical for AD (Traykov et al
2004; Giovannetti et al 2005; Golden et al 2005).Clinical Interventions in Aging 2006:1(3) 249
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Another line of research focuses on the identification of
specific predictors of developing vascular dementia in
groups of patients characterized by those pathologies which
are commonly considered as risk factors for
cardiovasculopathies such as diabetes and hypertension. The
evidence of slight and not evenly distributed signs of
cognitive impairment in hypertensive patients (Fioravanti
et al 1991) and its relationship with the daily temporal
distribution of elevated picks of systolic blood pressure
(more than with the level of high blood pressure of picks)
(Fioravanti et al 1996) can be considered as the evidence of
a progressive development of a cerebrovascular pathology
even before gross anatomical signs of abnormality can be
identified in the brain tissues. These findings provide support
for the proposal to introduce early therapeutic intervention
in patients with mild signs of cerebrovasculopathy or even
with risk factors for it (Schindler 2005).
Treatment of cognitive deficits
Attempts to treat symptoms of decline in
cerebrovasculopaties have been made since the first years
of the last century (Fioravanti 2003) starting with niacin
and continue today. At the beginning of the 1980s, citicoline
was used in these clinical areas after having been already in
use in treatment for stroke. In most of the clinical studies
with citicoline in VD, memory has been the principal end
point in the efficacy evaluation. There is a large experimental
database of experimental studies on memory and learning
performed on aged animals treated with citicoline. Most of
these studies have shown that treatment with citicoline
ameliorates cognitive deficits but does not necessarily
improve normal cognitive functions (Conant and Schauss
2004). The few studies done on memory in aged human
subjects with memory disorders, but no dementia, have
underlined the extreme variability of positive outcomes
depending on the type of patients and the kind of measures
used in the studies. Memory is a very complex and
multidimensional variable to quantify in humans and,
consequently, results from different studies which have in
common the assessment of memory are not necessarily
homogeneous and comparable if the specific modality of
memory evaluation is not taken into account. We have seen
that those studies which are trying to identify specific
patterns of memory disorders in vascular dementia are not
yet able to define a definite and reliable cognitive model of
functioning of these patients. As a consequence, it is almost
impossible to try to systematically apply a specific memory
parameter for the evaluation of treatment efficacy in this
clinical area, as it has been possible for AD. There is a
possibility that memory disorders might be contaminated
by other disorders attributable to executive function
including attention. This problem has been examined by
looking for methods of evaluating primary memory deficits
as distinct from those secondary to other cognitive
impairments external to memory per se (Fioravanti and Di
Cesare 1992).
Another relevant problem that emerges from a critical
analysis of the current and past literature is the relatively
poor reliability of single studies performed on small samples
of patients with various forms of vascular dementia (a further
level of complexity is derived by the different criteria given
to these patients in different periods of time). A metanalysis
is the best solution available for circumventing these
limitations. In the case of citicoline, a meta-analysis for
examining the reliability and validity of effects on memory
which have been studied in different ways and types of
patients in various studies, could fail to confirm the positive
results of the single studies once these data are pooled
together.
A metanalysis has been performed on the available
published and unpublished data obtained from controlled
clinical trials done with citicoline. This metanalysis carried
out according to the Cochrane Collaboration guidelines is
periodically updated in order to include all the studies
available (Fioravanti and Yanagi 2005).
Results of the metanalysis are divided by domains. This
allows for a comparative analysis between different areas
of assessment; for example, attention and memory. It is
possible to verify the homogeneity of results within each
domain.
Memory is one of the domains in this analysis and
includes results from 884 patients. While studies in this
domain include other types of patients as well as
cerebrovascular patients, there was no heterogeneity among
their results. This indicated that the effect of citicoline on
memory was significantly different from the placebo effect,
and did not specifically depend on the pathogenesis of the
cerebral disorder (effect size 0.19; confidence interval [CI]
95% 0.06, 0.32; p<0.005). In fact, when only
cerebrovascular disorders studies were pooled together (for
a total of 675 patients), the homogeneity and entity of results
was about the same (effect size 0.22; CI 95% 0.07, 0.37;
p<0.004).
Within the domain that deals with behavior control and
competence (a total of 814 patients), there was a citicoline
effect significantly different from placebo and independentClinical Interventions in Aging 2006:1(3) 250
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from type of measure and pathology examined (effect size
−0.26; CI 95% −0.49, −0.04; p<0.004). These results
coupled with those of the domain clinical evaluation of
improvement concerning a total of 217 patients (effect size
determined as the odds ratio of improving under active
treatment 8.89; CI 95% 5.19, 15.22; p<0.001) showed that
the cognitive effects of citicoline are clearly evident at the
behavioral level and can be easily appreciated with a clinical
observation of patients irrespective of the functional
paradigm used to measure them.
The attention domain, even though based on a substantial
number of 790 patients, revealed a large amount of variance
because of the large individual differences. These data did
not permit an interpretation of how much of the results
evidenced by memory measures can be considered as
specific of the “true” memory processes or as secondary to
an effect on other cognitive components of the cognitive
decline.
Finally, the tolerability of citicoline has never constituted
a problem whatever the modality of administration or the
dosage.
Conclusions
Treatment in patients with disorders attributed to a
cerebrovascular pathogenesis has a long history.
Unfortunately, many problems are still unresolved, including
the taxonomy of these disorders and a definition of cognitive
pattern of decline to be associated to this taxonomy. These
intrinsic problems have not helped to develop accepted
methods of research and treatment for these patients. Despite
these difficulties and elements of confusion between
different clinical studies performed at different periods of
time, citicoline has emerged as a valid treatment for patients
with chronic cerebrovascular disorders or with memory
problems.
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